Alternative donor transplantation for myelodysplastic syndromes: haploidentical relative and matched unrelated donors

被引：36

作者：

Grunwald, Michael R. ^{[1
]}

Zhang, Mei-Jie ^{[2
,3
]}

Elmariah, Hany ^{[4
]}

Johnson, Mariam H. ^{[3
]}

St Martin, Andrew ^{[3
]}

Bashey, Asad ^{[5
]}

Battiwalla, Minoo ^{[6
]}

Bredeson, Christopher N. ^{[7
,8
]}

Copelan, Edward ^{[1
]}

Cutler, Corey S. ^{[9
]}

George, Biju R. ^{[10
]}

Gupta, Vikas ^{[11
]}

Kanakry, Christopher ^{[12
]}

Mehta, Rohtesh S. ^{[13
]}

Milano, Filippo ^{[14
]}

Mussetti, Alberto ^{[15
]}

Nakamura, Ryotaro ^{[16
]}

Nishihori, Taiga ^{[4
]}

Saber, Wael ^{[3
]}

Solh, Melhem ^{[5
]}

Weisdorf, Daniel J. ^{[17
]}

Eapen, Mary ^{[3
]}

机构：

[1] Atrium Hlth, Dept Hematol Oncol & Blood Disorders, Levine Canc Inst, 1021 Morehead Med Dr,LCI Bldg 2,Suite 60100, Charlotte, NC 28204 USA

[2] Med Coll Wisconsin, Div Biostat, Inst Heath & Equ, Milwaukee, WI 53226 USA

[3] Med Coll Wisconsin, Dept Med, Ctr Int Blood & Marrow Transplant Res, Milwaukee, WI 53226 USA

[4] H Lee Moffitt Canc Ctr & Res Inst, Dept Blood & Marrow Transplant & Cellular Immunot, Tampa, FL USA

[5] Northside Hosp, Blood & Marrow Transplant Program, Atlanta, GA USA

[6] Sarah Cannon Blood & Marrow Transplant Ctr, Centennial Med Ctr, Div Hematol Oncol, Nashville, TN USA

[7] Ottawa Hosp, Blood & Marrow Transplant Program, Ottawa, ON, Canada

[8] Ottawa Hosp, Ottawa Hosp Res Inst, Ottawa, ON, Canada

[9] Dana Farber Canc Inst, Ctr Hematol Oncol, Boston, MA 02115 USA

[10] Christian Med Coll & Hosp, Div Hematol, Vellore, Tamil Nadu, India

[11] Univ Hlth Network, Princess Margaret Canc Ctr, Blood & Marrow Transplant Program, Toronto, ON, Canada

[12] NCI, Expt Transplantat & Immunol Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA

[13] MD Anderson Canc Ctr, Div Hematol Oncol, Houston, TX USA

[14] Fred Hutchinson Canc Res Ctr, Clin Res Div, 1124 Columbia St, Seattle, WA 98104 USA

[15] Inst Catala Oncol Hospitalet, Hematol Dept, Barcelona, Spain

[16] City Hope Natl Med Ctr, Dept Hematol & Hematopoiet Cell Transplantat, Duarte, CA USA

[17] Univ Minnesota, Dept Med, Div Hematol Oncol & Transplantat, Box 736 UMHC, Minneapolis, MN 55455 USA

来源：

BLOOD ADVANCES | 2021年 / 5卷 / 04期

基金：

美国国家卫生研究院;

关键词：

HEMATOPOIETIC-CELL TRANSPLANTATION; ACUTE MYELOID-LEUKEMIA; POSTTRANSPLANTATION CYCLOPHOSPHAMIDE; BONE-MARROW; OLDER; SURVIVAL; BLOOD; CONSENSUS; OUTCOMES; GRAFTS;

D O I：

10.1182/bloodadvances.2020003654

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

We compared outcomes in 603 patients with myelodysplastic syndrome (MDS) after HLA-haploidentical relative (n = 176) and HLA-matched unrelated (n = 427) donor hematopoietic cell transplantation (HCT) from 2012 to 2017, using the Center for International Blood and Marrow Transplant Research database. All transplantations used reduced-intensity conditioning regimens. Total-body irradiation plus cyclophosphamide and fludarabine was the predominant regimen for HLA-haploidentical relative donor HCT, and graft-versus-host disease (GVHD) prophylaxis was uniformly posttransplantation cyclophosphamide, calcineurin inhibitor, and mycophenolate. Fludarabine with busulfan or melphalan was the predominant regimen for HLA-matched unrelated donor HCT, and GVHD prophylaxis was calcineurin inhibitor with mycophenolate or methotrexate. Results of multivariate analysis revealed higher relapse (hazard ratio [HR], 1.56; P = .0055; 2-year relapse rate, 48% vs 33%) and lower disease-free survival (DFS) rates after HLA-haploidentical relative donor HCT (HR, 1.29; P = .042; 2-year DFS, 29% vs 36%). However, overall survival (OS) rates did not differ between donor type (HR, 0.94; P = .65; 2-year OS, 46% for HLA-haploidentical and 44% for HLA-matched unrelated donor HCT) because of mortality associated with chronic GVHD. Acute grade 2 to 4 GVHD (HR, 0.44; P < .0001) and chronic GVHD (HR, 0.36; P < .0001) were lower after HLA-haploidentical relative donor HCT. By 2 years, probability of death resulting from chronic GVHD was lower after HLA-haploidentical relative compared with HLA-matched unrelated donor HCT (6% vs 21%), negating any potential survival advantage from better relapse control. Both donor types extend access to transplantation for patients with MDS; strategies for better relapse control are desirable for HLA-haploidentical relative donor HCT, and effective GVHD prophylaxis regimens are needed for unrelated donor HCT.

引用

页码：975 / 983

页数：9

共 30 条

[1]

Andersen PK, 1999, STAT MED, V18, P1489, DOI 10.1002/(SICI)1097-0258(19990630)18:12<1489::AID-SIM140>3.0.CO

[2]

2-#

[3]

ATKINSON K, 1989, BONE MARROW TRANSPL, V4, P247

[4] Defining the Intensity of Conditioning Regimens: Working Definitions [J].

Bacigalupo, Andrea ;

Ballen, Karen ;

Rizzo, Doug ;

Giralt, Sergio ;

Lazarus, Hillard ;

Ho, Vincent ;

Apperley, Jane ;

Slavin, Shimon ;

Pasquini, Marcelo ;

Sandmaier, Brenda M. ;

Barrett, John ;

Blaise, Didier ;

Lowski, Robert ;

Horowitz, Mary .

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2009, 15 (12) :1628-1633

[5] Mobilized Peripheral Blood Stem Cells Versus Unstimulated Bone Marrow As a Graft Source for T-Cell-Replete Haploidentical Donor Transplantation Using Post-Transplant Cyclophosphamide [J].

Bashey, Asad ;

Zhang, Mei-Jie ;

McCurdy, Shannon R. ;

St Martin, Andrew ;

Argall, Trevor ;

Anasetti, Claudio ;

Ciurea, Stefan O. ;

Fasan, Omotayo ;

Gaballa, Sameh ;

Hamadani, Mehdi ;

Munshi, Pashna ;

Al Malki, Monzr M. ;

Nakamura, Ryotaro ;

O'Donnell, Paul V. ;

Perales, Miguel-Angel ;

Raj, Kavita ;

Romee, Rizwan ;

Rowley, Scott ;

Rocha, Vanderson ;

Salit, Rachel B. ;

Solh, Melhem ;

Soiffer, Robert J. ;

Fuchs, Ephraim Joseph ;

Eapen, Mary .

JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (26) :3002-+

[6] Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203) [J].

Bolanos-Meade, Javier ;

Reshef, Ran ;

Fraser, Raphael ;

Fei, Mingwei ;

Abhyankar, Sunil ;

Al-Kadhimi, Zaid ;

Alousi, Amin M. ;

Antin, Joseph H. ;

Arai, Sally ;

Bickett, Kate ;

Chen, Yi-Bin ;

Damon, Lloyd E. ;

Efebera, Yvonne A. ;

Geller, Nancy L. ;

Giralt, Sergio A. ;

Hari, Parameswaran ;

Holtan, Shernan G. ;

Horowitz, Mary M. ;

Jacobsohn, David A. ;

Jones, Richard J. ;

Liesveld, Jane L. ;

Logan, Brent R. ;

MacMillan, Margaret L. ;

Mielcarek, Marco ;

Noel, Pierre ;

Pidala, Joseph ;

Porter, David L. ;

Pusic, Iskra ;

Sobecks, Ronald ;

Solomon, Scott R. ;

Weisdorf, Daniel J. ;

Wu, Juan ;

Pasquini, Marcelo C. ;

Koreth, John .

LANCET HAEMATOLOGY, 2019, 6 (03) :E132-E143

[7] Haploidentical Transplantation for Older Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome [J].

Ciurea, Stefan O. ;

Shah, Mithun, V ;

Saliba, Rima M. ;

Gaballa, Sameh ;

Kongtim, Piyanuch ;

Rondon, Gabriela ;

Chen, Julianne ;

Wallis, Whitney ;

Cao, Kai ;

Konopleva, Marina ;

Daver, Naval ;

Cortes, Jorge ;

Ravandi, Farhad ;

Alousi, Amin ;

Ahmed, Sairah ;

Popat, Uday ;

Parmar, Simrit ;

Bashir, Qaiser ;

Betul, Oran ;

Hosing, Chitra ;

Shpall, Elizabeth J. ;

Rezvani, Katayoun ;

Khouri, Issa F. ;

Kebriaei, Partow ;

Champlin, Richard E. .

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2018, 24 (06) :1232-1236

[8] Incidence and Burden of the Myelodysplastic Syndromes [J].

Cogle, Christopher R. .

CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 2015, 10 (03) :272-281

[9]

COX DR, 1972, J R STAT SOC B, V34, P187

[10] Current Use of and Trends in Hematopoietic Cell Transplantation in the United States [J].

D'Souza, Anita ;

Fretham, Caitrin ;

Lee, Stephanie J. ;

Arora, Mukta ;

Brunner, Janet ;

Chhabra, Saurabh ;

Devine, Steven ;

Eapen, Mary ;

Hamadani, Mehdi ;

Hari, Parameswaran ;

Pasquini, Marcelo C. ;

Perez, Waleska ;

Phelan, Rachel A. ;

Riches, Marcie L. ;

Rizzo, J. Douglas ;

Saber, Wael ;

Shaw, Bronwen E. ;

Spellman, Stephen R. ;

Steinert, Patricia ;

Weisdorf, Daniel J. ;

Horowitz, Mary M. .

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2020, 26 (08) :E177-E182

← 1 2 3 →